- Home
- ZNTL
as 02-21-2025 4:00pm EST
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 134.7M | IPO Year: | 2020 |
| Target Price: | $8.53 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $18.07 | Next Earning Date: | 03-04-2025 |
| Revenue: | $40,560,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Zentalis Pharmaceuticals Inc. (ZNTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bruns Ingmar | ZNTL | Chief Medical Officer | Feb 6 '25 | Buy | $2.28 | 20,000 | $45,656.00 | 36,629 | |
| Vultaggio Vincent | ZNTL | PAO and Interim PFO | Feb 3 '25 | Sell | $1.71 | 2,615 | $4,475.57 | 189,826 | |
| Lackner Mark | ZNTL | Chief Scientific Officer | Feb 3 '25 | Sell | $1.71 | 14,368 | $24,590.83 | 512,856 | |
| Paul Andrea | ZNTL | Chief Legal Officer | Feb 3 '25 | Sell | $1.71 | 13,230 | $22,643.15 | 1,070,784 | |
| Walker Luke Nathaniel | ZNTL | Director | Jan 31 '25 | Buy | $1.76 | 14,200 | $24,966.44 | 86,681 | |
| Skvarka Jan | ZNTL | Director | Jan 31 '25 | Buy | $1.72 | 60,000 | $103,446.00 | 149,551 | |
| EASTLAND JULIA MARIE | ZNTL | CEO & President | Jan 31 '25 | Buy | $1.73 | 28,500 | $49,344.90 | 28,500 | |
| Lackner Mark | ZNTL | Chief Scientific Officer | Jan 2 '25 | Sell | $3.12 | 4,411 | $13,762.32 | 512,856 |
Latest Zentalis Pharmaceuticals Inc. News
ZNTL Breaking Stock News: Dive into ZNTL Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently
Argus Research
17 days ago
Daily – Vickers Top Buyers & Sellers for 02/05/2025
GlobeNewswire
19 days ago
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zacks
19 days ago
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
TipRanks
23 days ago
Zentalis price target lowered to $10 from $20 at Oppenheimer
GlobeNewswire
24 days ago
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
MT Newswires
24 days ago
Zentalis Pharmaceuticals to Cut 40% of Workforce
GlobeNewswire
25 days ago
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
Compare ZNTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZNTL Zentalis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.